首页> 美国卫生研究院文献>Oncotarget >Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells
【2h】

Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells

机译:基于阵列的全基因组RNAi筛选可鉴定可增强人类癌细胞中p53相关凋亡的shRNA

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

p53 transduction is a potentially effective cancer therapy but does not result in a good therapeutic response in all human cancers due to resistance to apoptosis. To discover factors that overcome resistance to p53-induced apoptosis, we attempted to identify RNAi sequences that enhance p53-induced apoptosis. We screened a genome-wide lentiviral shRNA library in liver cancer Huh-7 and pancreatic cancer Panc-1 cells, both of which resist p53-induced apoptosis. After the infection of adenovirus expressing p53 or LacZ as a control, shRNA-treated populations were analyzed by microarray. We identified shRNAs that were significantly decreased in p53-infected cells compared with control cells. Among these shRNAs, shRNA-58335 was markedly decreased in both cancer cell lines tested. shRNA-58335 enhanced p53-related apoptosis in vitro and augmented the inhibitory effect of adenoviral p53 transduction on tumor growth in vivo. Furthermore, the enhanced apoptotic response by shRNA-58335 was also confirmed by treatment with PRIMA-1, which reactivates mutant p53, instead of adenoviral p53 transduction. We found that shRNA-58335 evokes the apoptotic response following p53 transduction or functional restoration of p53 with a small molecule drug in cancer cells resistant to p53-induced apoptosis. The combination of p53 restoration and RNAi-based drugs is expected to be a promising novel cancer therapy.
机译:p53转导是一种潜在有效的癌症治疗方法,但由于对细胞凋亡的抗性,在所有人类癌症中均未产生良好的治疗反应。为了发现克服p53诱导的细胞凋亡抗性的因素,我们尝试鉴定增强p53诱导的细胞凋亡的RNAi序列。我们在肝癌Huh-7和胰腺癌Panc-1细胞中筛选了全基因组慢病毒shRNA文库,两者均抗p53诱导的细胞凋亡。感染表达p53或LacZ的腺病毒作为对照后,通过微阵列分析shRNA处理的群体。我们鉴定出与对照细胞相比,在经p53感染的细胞中,shRNA明显减少。在这些shRNA中,shRNA-58335在两种测试的癌细胞系中均显着降低。 shRNA-58335在体外增强了p53相关的凋亡,并增强了腺病毒p53转导对体内肿瘤生长的抑制作用。此外,通过PRIMA-1的处理也证实了shRNA-58335增强的凋亡反应,该试剂可重新激活突变体p53,而不是腺病毒p53转导。我们发现shRNA-58335在抗p53诱导的细胞凋亡的癌细胞中激活p53转导或用小分子药物恢复p53功能后引发凋亡反应。 p53恢复和基于RNAi的药物的组合有望成为一种有前途的新型癌症治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号